Menu Search
Equities

Avanos Medical Inc

8HH:MUN

Avanos Medical Inc

Actions
  • Price (EUR)14.20
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change-20.22%
  • Beta--
Data delayed at least 15 minutes, as of Mar 10 2025 07:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Avanos Medical Inc's net income fell 534.47% from a loss of 61.80m to a larger loss of 392.10m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 43.61% to 44.56%.
Gross margin55.44%
Net profit margin-56.16%
Operating margin-57.60%
Return on assets-27.14%
Return on equity-37.42%
Return on investment-31.58%
More ▼

Cash flow in USDView more

In 2024, Avanos Medical Inc increased its cash reserves by 22.81%, or 20.00m. The company earned 100.70m from its operations for a Cash Flow Margin of 14.64%. In addition the company used 27.50m on investing activities and also paid 49.10m in financing cash flows.
Cash flow per share-7.36
Price/Cash flow per share--
Book value per share18.03
Tangible book value per share5.67
More ▼

Balance sheet in USDView more

Avanos Medical Inc has a Debt to Total Capital ratio of 13.99%, a higher figure than the previous year's 12.89%.
Current ratio2.37
Quick ratio1.53
Total debt/total equity0.1626
Total debt/total capital0.1399
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.